The FDA has cleared the first-ever human trial of epigenetic reprogramming longevity therapy, while an AI model published in Cell identifies new drug candidates at unprecedented speed. Together with a…
A generative AI-designed drug has delivered clinical proof in a Phase IIa trial, while new biological age clocks and microbiome science are completing the precision longevity toolkit. Here is what…
The first human trial of partial epigenetic reprogramming has launched, an AI platform published in Cell is accelerating longevity drug discovery, and a landmark NEJM trial proves cardiovascular primary prevention…
Three landmark studies in late 2025 and early 2026 reveal that gut bacteria, cellular NAD+ balance, and epigenetic clock acceleration are key drivers of biological aging and, in animal models,…
Three landmark breakthroughs in longevity reprogramming research 2026 are reshaping what science knows about human aging. An AI-designed drug proves itself in clinical trials, the first human epigenetic reprogramming trial…
Three landmark developments are rewriting the rules of longevity medicine: cardiovascular prevention now starting at age 30, an AI platform published in Cell discovering treatments for liver cancer and pulmonary…
Two landmark studies reveal that human aging is not gradual. Your body undergoes three distinct molecular upheavals around ages 44, 50, and 60, with blood vessels leading the decline. Here…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.